ArticleEuropean journal of medical research2025
Unveiling the role of coagulation-related genes in acute myeloid leukemia prognosis and immune microenvironment through machine learning.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute Myeloid Leukemia (AML) is a highly heterogeneous hematologic malignancy influenced by various factors affecting prognosis. Recently, the role of coagulation-related genes in tumor biology has garnered increasing attention. This study aims to investigate the expression patterns of coagulation-related genes in AML and their clinical relevance.
methodsWe obtained RNA-seq data and clinical information for AML patients from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO), followed by data cleaning and normalization. Unsupervised consensus clustering was performed to identify molecular subtypes, and Kaplan-Meier survival analysis was utilized to assess survival differences. We further identified differentially expressed genes (DEGs) between groups and conducted functional enrichment analyses. Additionally, a prognostic model was constructed using machine learning techniques, and its prognostic ability was validated.
resultsClustering analysis categorized 151 tumor samples into the high coagulation-related gene expression group (C1, high-expression) and the low coagulation-related gene expression group (C2, low-expression), revealing 1,747 DEGs. Functional enrichment analysis indicated that DEGs were mainly associated with leukocyte migration and cytokine signaling pathways. Immune landscape analysis showed that the high expression group had elevated immune and stromal scores, distinct immune cell infiltration patterns, and a higher ESTIMATE score. The constructed coagulation score risk model indicated that age, cytogenetics, and risk scores were significantly associated with AML prognosis. Furthermore, intersection analysis using three machine learning methods identified MMP7 and F12 as key biomarkers.
conclusionOur study demonstrates that coagulation-related genes play a crucial role in the molecular characteristics, prognostic assessment, and immune modulation in AML. MMP7 and F12 are highlighted as potential biomarkers that could aid in optimizing the diagnosis and treatment strategies for AML. These findings offer new insights into personalized therapies for AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.